NCT03967223: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 103 taking part
- Started
- 31 Dec 2019
- Primary completion
- 1 Mar 2024
- Arms
- Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS, Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo
- Results
- None posted
- 30 May 2019: Trial registered
- 31 Dec 2019: Trial started